Consultants Tapped To Help FDA With Post-Approval Study Mandates
This article was originally published in The Gray Sheet
FDA has hired outside help to improve the process for imposing clinical study requirements after a company's product is approved for marketing
You may also be interested in...
The recent shift of responsibility for device condition-of-approval studies to the FDA's Office of Surveillance & Biometrics could result in more elaborate and burdensome study requirements if device firms are not careful, speakers warned at this year's Regulatory Affairs Professionals Society annual meeting
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.